Drug intelligence / Profile preview

PHN017

Development stage: Unknown
Lead developer: PhytoHealth
Modality: Small Molecules

Overview

PHN017 is a botanical small molecule drug candidate developed by Phyto Health Corporation, currently in Phase 1 clinical development. It is specifically designed to address the "cytokine storm"—a life-threatening systemic inflammatory response—triggered by severe infectious diseases, including viral and bacterial infections such as COVID-19 or sepsis. As a botanical drug, PHN017 aims to modulate the immune system's overproduction of pro-inflammatory cytokines, potentially preventing multi-organ failure and improving survival rates in critically ill patients.

Targets

IL10 (Interleukin-10)

Beyond the preview

Go deeper on PHN017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHN017.

Explore the full profile